A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

Overview

To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis.

Full Title of Study: “Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Primary Purpose: Treatment

Interventions

  • Drug: Flucytosine
  • Drug: Fluconazole
  • Drug: Amphotericin B

Participating in This Clinical Trial

Inclusion Criteria Concurrent Medication: Allowed:

  • Immunosuppressant therapy. – Antiviral therapy such as zidovudine. – Prophylaxis for Pneumocystis carinii pneumonia. Concurrent Treatment: Allowed: – Radiation therapy for mucocutaneous Kaposi's sarcoma. Written informed consent must be obtained for each patient, either from the patient himself or from the patient's legal guardian. – No prior systemic antifungal therapy for cryptococcosis. – Relapse after prior therapy. – Success of prior therapy must have been documented by negative cerebrospinal fluid (CSF) culture at the end of therapy. Following prior therapy, such patients may not have received more than 1 mg/kg/wk amphotericin B in the 4 weeks before entry into study. Prior Medication: Allowed: – Immunosuppressant therapy. – Antiviral therapy (such as zidovudine). – Prophylaxis for Pneumocystis carinii pneumonia. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: – Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis. – History of allergy to or intolerance of imidazoles, azoles, or amphotericin B. – Moderate or severe liver disease. – Comatose. – Unlikely to survive more than 2 weeks. – Any exceptions to these prohibitions of concomitant medications must be approved by Pfizer Central Research. Concurrent Medication: Excluded: – Coumadin-type anticoagulants. – Oral hypoglycemics. – Barbiturates. – Phenytoin. – Immunostimulants. – Investigational drugs or approved (licensed) drugs for investigational indications. – Any exceptions to these prohibitions of concomitant medications must be approved by Pfizer Central Research. – Excluded within 4 weeks of study entry: – Greater than 1 mg/kg/wk amphotericin B. Concurrent Treatment: Excluded: – Lymphocyte replacement. Patients with the following are excluded: – Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis. – History of allergy to or intolerance of imidazoles, azoles, or amphotericin B. – Moderate or severe liver disease. – Comatose. – Unlikely to survive more than 2 weeks. Prior Medication: Excluded: – Coumadin-type anticoagulants. – Oral hypoglycemics. – Barbiturates. – Phenytoin. – Immunostimulants. – Investigational drugs or approved (licensed) drugs for investigational indications. – Excluded within 4 weeks of study entry: – Greater than 1 mg/kg/wk amphotericin B. Prior Treatment: Excluded: – Lymphocyte replacement.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Pfizer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.